Treatment Options for Invasive Fungal Infections: Why They Don't Always Work

Treatment Options for Invasive Fungal Infections: Why They Don't Always Work

ReachMD Healthcare Image

Treatment options for invasive fungal infections are limited, but that’s changing. Find out what’s on the horizon and how to best fight the fungus.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The changing epidemiology of invasive fungal infections, ongoing antifungal resistance, drug-drug interactions, and few oral agents leave patients with limited viable treatment options. While the antifungal pipeline has been essentially dry for the past 2 decades, several antifungal drugs are now in late-stage clinical development and poised to address these unmet needs. But take heed: They will need to be treated as precious commodities lest they, too, become ineffective due to resistance.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Thomas F. Patterson, MD, FACP, FIDSA
    Chief, Division of Infectious Diseases
    Director, San Antonio Center for Medical Mycology
    The University of Texas Health Science Center at San Antonio
    San Antonio, TX

    Consulting Fees: Basilea, F2G, Gilead, Pfizer, Sufunga
    Contracted Research: Cidara, F2G, Gilead
    Royalties: UpToDate

    George R. Thompson, III, MD
    Professor of Medicine
    Department of Internal Medicine, Division of Infectious Diseases
    Department of Medical Microbiology and Immunology
    University of California, Davis Health
    Davis, CA

    Consultant: Amplyx Pharmaceuticals, Inc., Astellas, F2G, Mayne Pharma, Pfizer 
    Grant/Research Support: Amplyx Pharmaceuticals, Inc., Astellas, F2G, Mayne Pharma, Pfizer, Toyoma Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Susan L. Smith, MN, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify reasons why invasive fungal infection (IFI) treatments fail
    • Explain how the changing ecology of IFIs and rare invasive mold infections has created unmet treatment needs
    • Demonstrate improved ability to practice antifungal stewardship
  • Target Audience

    This activity is designed to meet the educational needs of hematologists/oncologists, infectious disease specialists, internists, and others who treat invasive fungal infections.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from F2G, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free